These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 34533779)

  • 1. Migraine Characteristics, Comorbidities, Healthcare Resource Utilization, and Associated Costs of Early Users of Erenumab in the USA: A Retrospective Cohort Study Using Administrative Claims Data.
    Chandler D; Szekely C; Aggarwal S; Cyprien L; Bensink M
    Pain Ther; 2021 Dec; 10(2):1551-1566. PubMed ID: 34533779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in Use of Migraine Medications, Healthcare Resource Utilization, and Associated Direct Costs Over 12 Months Following Initiation of Erenumab: A US Retrospective Real-World Analysis.
    Urman R; Princic N; Vuvu F; Patel LB; Oh S; Chandler D; Hindiyeh N; Bensink ME
    Pain Ther; 2024 Oct; 13(5):1299-1313. PubMed ID: 39177937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare costs and resource utilization in patients with migraine treated with erenumab: A retrospective, non-interventional study using claims data from the United States.
    Tepper SJ; Schwedt TJ; Vo P; Thompson J; Joshi P; Abdrabboh A; Ferraris M; Tiwari S
    Headache; 2023; 63(10):1423-1436. PubMed ID: 37655551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erenumab patient characteristics, medication adherence, and treatment patterns in the United States.
    Hines DM; Shah S; Multani JK; Wade RL; Buse DC; Bensink M
    Headache; 2021 Apr; 61(4):590-602. PubMed ID: 33594672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study.
    Tepper SJ; Fang J; Vo P; Shen Y; Zhou L; Abdrabboh A; Glassberg M; Ferraris M
    J Headache Pain; 2021 Apr; 22(1):27. PubMed ID: 33874884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in use of acute and preventive medications for migraine after erenumab initiation over 12 months: A United States retrospective cohort study.
    Multani JK; Urman R; Park AS; Gill K; Vuvu F; Sun K; Patel LB; Stockl KM; Hawkins K; Rhyne C; Bensink ME
    Headache; 2024 Sep; ():. PubMed ID: 39248147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Treatment Profiles, Clinical Outcomes, and Healthcare Resource Utilization of Patients with Migraine Prescribed Erenumab: A Multicenter Chart-Review Study of US Headache Centers.
    Faust E; Pivneva I; Yang K; Betts KA; Ahmed Z; Joshi S; Hogan R; Blumenfeld A; Schim J; Feoktistov A; Carnes K; Bensink M; Wu EQ; Chou DE; Chandler D
    Neurol Ther; 2021 Jun; 10(1):293-306. PubMed ID: 33856626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response.
    Buse DC; Krasenbaum LJ; Seminerio MJ; Packnett ER; Carr K; Ortega M; Driessen MT
    Pain Ther; 2024 Jun; 13(3):511-532. PubMed ID: 38472655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Trends in Characteristics of Patients with Migraine Newly Initiated on Erenumab in the USA: A Retrospective Analysis.
    Fang J; Korrer S; Johnson JC; Cheadle MA; Shah R; Ferraris ML; Lopez-Lopez C
    Adv Ther; 2021 Jun; 38(6):2921-2934. PubMed ID: 33763828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine.
    Robblee J; Devick KL; Mendez N; Potter J; Slonaker J; Starling AJ
    Headache; 2020 Oct; 60(9):2014-2025. PubMed ID: 32920850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resource utilization impact of topiramate for migraine prevention in the managed-care setting.
    Wertz DA; Quimbo RM; Yaldo AZ; Rupnow MF
    Curr Med Res Opin; 2009 Feb; 25(2):499-503. PubMed ID: 19192995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real-world study.
    Gladstone J; Chhibber S; Minhas J; Neish CS; Power GS; Lan Z; Rochdi D; Lanthier-Martel J; Bastien N
    Headache; 2022 Jan; 62(1):78-88. PubMed ID: 34807454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.
    Bonafede M; Sapra S; Shah N; Tepper S; Cappell K; Desai P
    Headache; 2018 May; 58(5):700-714. PubMed ID: 29446063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Patterns, Healthcare Resource Utilization, and Direct Costs Among Patients Initiating Concomitant Use of a Calcitonin Gene-Related Peptide Monoclonal Antibody (CGRP mAb) and Novel Acute Medication in the United States.
    Varnado OJ; Gulati T; Wheeler A; Hoyt M
    Patient Prefer Adherence; 2023; 17():3449-3459. PubMed ID: 38143945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
    Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F;
    Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 3-year follow-up study of outcomes associated with patterns of traditional acute and preventive migraine treatment: An administrative claims-based cohort study in the United States.
    Joshi S; Spargo A; Hoyt M; Panni T; Viktrup L; Kim G; Hasan A; Liu YY; Zakharyan A
    Headache; 2024; 64(7):796-809. PubMed ID: 38898657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topiramate in migraine prophylaxis: long-term impact on resource utilization and cost.
    Silberstein SD; Feliu AL; Rupnow MF; Blount AC; Boccuzzi SJ
    Headache; 2007 Apr; 47(4):500-10. PubMed ID: 17445099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of rimegepant utilization patterns and patient characteristics among new users: a United States administrative claims-based study.
    Ailani J; Lewis M; Dai F; Jenkins A; Cirillo J; Hygge Blakeman K; Abraham L; Brown J
    Curr Med Res Opin; 2024 Nov; 40(11):1913-1920. PubMed ID: 39340768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.
    Runken MC; Goodwin B; Shah M; Eaddy M; D'Souza A; Bowers B; Bell CF
    Appl Health Econ Health Policy; 2015 Feb; 13(1):109-20. PubMed ID: 25294555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ixekizumab Treatment Patterns and Health Care Resource Utilization Among Patients with Axial Spondyloarthritis: A Retrospective United States Claims Database Study.
    Danve A; Vadhariya A; Lisse J; Cholayil A; Bansal N; Bello N; Bakewell C
    Rheumatol Ther; 2024 Oct; 11(5):1333-1345. PubMed ID: 39162898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.